GlassScriptPhysician profile
Mia Allmond
NPI 1316633316
$3,128.64
in general payments reported to CMS, 2019-2025
22 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what 96% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $489 · 2024: $1,235 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,054 · Education: $74.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,053.66 |
| Education | $74.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $260.57 | 2024-2025 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $258.82 | 2024 | |
| Axsome Therapeutics, INC. | $245.52 | 2025 | Symbravo |
| Sage Therapeutics, LLC | $219.52 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $215.52 | 2024-2025 | Uzedy |
| Neurelis, INC. | $149.20 | 2023-2024 | Valtoco |
| Madrigal Pharmaceuticals | $148.28 | 2025 | Rezdiffra |
| Medtronic, INC. | $147.23 | 2025 | Symplicity G3 |
| Mirum Pharmaceuticals, INC. | $142.37 | 2023 | Livmarli |
| Genzyme Corporation | $133.14 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $125.59 | 2024-2025 | |
| Stryker Corporation | $124.99 | 2025 | Mild Device Kit |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $120.99 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $120.34 | 2025 | Arexvy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $117.18 | 2024 | |
| Bioxcel Therapeutics, INC. | $104.64 | 2023 | Igalmi |
| Exact Sciences Corporation | $98.67 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $87.43 | 2025 | |
| Tanabe Pharma America, INC. | $74.98 | 2025 | Radicava |
| Ucb, INC. | $72.80 | 2024 | Briviact |
| Alnylam Pharmaceuticals INC. | $35.87 | 2023 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mia Allmond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.